<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d493" origId="Bretylium"><sentence id="DrugDDI.d493.s0" origId="s0" text="Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection."><entity charOffset="63-77" id="DrugDDI.d493.s0.e0" origId="s0.p5" text="norepinephrine" type="drug"/><entity charOffset="88-116" id="DrugDDI.d493.s0.e1" origId="s0.p7" text="Bretylium Tosylate Injection" type="drug"/><pair e1="DrugDDI.d493.s0.e0" e2="DrugDDI.d493.s0.e1" id="DrugDDI.d493.s0.p0" interaction="true"/></sentence><sentence id="DrugDDI.d493.s1" origId="s1" text="The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate."><entity charOffset="4-19" id="DrugDDI.d493.s1.e0" origId="s1.p8" text="pressor effects" type="drug"/><entity charOffset="46-54" id="DrugDDI.d493.s1.e1" origId="s1.p10" text="dopamine" type="drug"/><entity charOffset="58-72" id="DrugDDI.d493.s1.e2" origId="s1.p12" text="norepinephrine" type="drug"/><entity charOffset="89-107" id="DrugDDI.d493.s1.e3" origId="s1.p15" text="Bretylium Tosylate" type="drug"/><pair e1="DrugDDI.d493.s1.e0" e2="DrugDDI.d493.s1.e1" id="DrugDDI.d493.s1.p0" interaction="false"/><pair e1="DrugDDI.d493.s1.e0" e2="DrugDDI.d493.s1.e2" id="DrugDDI.d493.s1.p1" interaction="false"/><pair e1="DrugDDI.d493.s1.e0" e2="DrugDDI.d493.s1.e3" id="DrugDDI.d493.s1.p2" interaction="false"/><pair e1="DrugDDI.d493.s1.e1" e2="DrugDDI.d493.s1.e2" id="DrugDDI.d493.s1.p3" interaction="false"/><pair e1="DrugDDI.d493.s1.e1" e2="DrugDDI.d493.s1.e3" id="DrugDDI.d493.s1.p4" interaction="true"/><pair e1="DrugDDI.d493.s1.e2" e2="DrugDDI.d493.s1.e3" id="DrugDDI.d493.s1.p5" interaction="true"/></sentence><sentence id="DrugDDI.d493.s2" origId="s2" text="When catecholamines are administered, dilute solutions should be used and blood pressure should be monitored closely."/><sentence id="DrugDDI.d493.s3" origId="s3" text="Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy."><entity charOffset="80-89" id="DrugDDI.d493.s3.e0" origId="s3.p36" text="lidocaine" type="drug"/><entity charOffset="94-112" id="DrugDDI.d493.s3.e1" origId="s3.p38" text="Bretylium Tosylate" type="drug"/><entity charOffset="120-125" id="DrugDDI.d493.s3.e2" origId="s3.p39" text="drugs" type="drug"/><pair e1="DrugDDI.d493.s3.e0" e2="DrugDDI.d493.s3.e1" id="DrugDDI.d493.s3.p0" interaction="false"/><pair e1="DrugDDI.d493.s3.e0" e2="DrugDDI.d493.s3.e2" id="DrugDDI.d493.s3.p1" interaction="false"/><pair e1="DrugDDI.d493.s3.e1" e2="DrugDDI.d493.s3.e2" id="DrugDDI.d493.s3.p2" interaction="false"/><negationtags>Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently &lt;xcope&gt;&lt;cue&gt;without&lt;/cue&gt; any evidence of interactions resulting in adverse effects or diminished efficacy&lt;/xcope&gt;.</negationtags></sentence></document>